Abstract: There are provided a metal material for electrode formation, which can form an electrode provided in an organic function element without adopting vapor deposition, can easily realize an increase in size, can reduce production cost, and does not cause any disconnection of the electrode upon exposure to flexure and, thus, is highly reliable, and, at the same time, has a high level of electron injection function, and an organic function element using the metal material. The metal material is a Ga(gallium)-base alloy which is in a paste state at a temperature of the melting point of the Ga-base alloy or above, the Ga-base alloy comprising at least a Ga-base liquid metal in a liquid state at room temperature and an alkali metal or an alkaline earth metal and having an electron injection function.

Abstract: A highly-reliable, inexpensive and small-sized automatic analyzer is provided which can eliminate the need of an additional space for piercing a seal of a reagent bottle and can prevent a deviation of a reagent sampling nozzle from the position of a pierced hole. A piercing tool for piercing the seal of the reagent bottle is fitted over a nozzle of a reagent sampling mechanism, and a stripper for automatically fitting and removing the piercing tool is provided. By fitting the piercing tool for piercing the seal of the reagent bottle over the nozzle of the reagent sampling mechanism, the seal of the reagent bottle can be pierced in situ on a reagent disk by using the piercing tool. An additional space so far required for the seal piercing is no longer needed and a deviation between the seal piercing position and the reagent sampling position is prevented.

Abstract: A machine for processing samples of biological tissues or the like, comprising a box-like structure, which delimits a compartment for accommodating trays for containing sample treatment liquid (the trays being arranged in preset positions of the compartment), and racks for supporting at least one sample supporting slide to be inserted in the trays. The machine comprises elements for transfer within the compartment for the trays and the racks, both individually and with the racks inserted in the trays.

Abstract: A reactor assembly for analysing the effluent stream from at least one flow-through reactor, The reactor includes a flow-through reactor for performing at least one chemical reaction. The flow-through reactor includes a reaction chamber including a reaction zone, the reaction chamber being connected to a reactor inlet for a reactant, upstream of the reaction zone and a reactor outlet for the effluent stream from the reaction zone, downstream of the reaction zone; and an analyser for subjecting the effluent stream to an analysing procedure, each reactor outlet being connected to an analyser by an effluent conduit. The reactor assembly further includes a dilution fluid supply member for adding a dilution fluid to the effluent stream, downstream of the reaction zone.

Abstract: This invention relates to a carbon black reactor comprising; a combustion zone for generating a hot combustion gas by burning a mixture of a hydrocarbon fuel and an oxygen containing gas, a reaction zone for producing a carbon black by contacting the hot combustion gas with a feedstock introduced in a plurality of divided flows to thermally decompose and/or incompletely combust the feedstock, and a quench zone for stopping a carbon black growth reaction by injection a coolant to said carbon black containing flow, and these three zones are arrayed laterally in order, wherein the cross-section shape of the feedstock introduction part in the reaction zone is not a circle nor a polygon. The carbon black reactor can produce the carbon black having same characteristics, especially the distribution of the aggregate size, as one produced by pilot-scale reactor, while its production scale is increased to the level of that of reactor actually operated.

Abstract: A pre-reformer (10) comprises a non-electrically conducting gas tight duct (12) and an electrically conducting wire (14) arranged in the duct (12). The electrically conducting wire (14) is electrically isolated from the duct (12). The duct (12) has an inlet (16) for receiving a hydrocarbon fuel at a first end (18) and an outlet (20) for supplying a pre-reformed hydrocarbon fuel at a second end (22). At least the inner surface (24) of the duct (12) is chemically inert with respect to the hydrocarbon fuel. An electrical power supply (26) is electrically connected to the electrically conducting wire (14) and a control means (28) controls the supply of electrical current through the electrically conducting wire (14) to maintain the electrically conducting wire (14) at a temperature to provide selective thermal decomposition of higher hydrocarbons in the hydrocarbon fuel. The performer reduces coking in associated fuel cells and other parts of a fuel cell system.

Abstract: A catalyst holding filter reducing a pressure loss. A catalyst holding filter (10) is made of a ceramic support (4) of SiC covered with a catalyst layer (2). An average pore size of the ceramic support is 10-250 ?m, and a porosity of the ceramic support is 40-80%. The catalyst layer contains a catalyst, a cocatalyst and a support material.

Abstract: A method for manufacturing isotope-doped carbon nanotubes (10) includes the steps of: (a) providing a carbon rod (209) connected with an anode (214) of an electrical source, the carbon rod including at least two kinds of carbon isotope segments (202, 203) arranged therealong according to need; (b) providing a pure carbon rod (208) connected with a cathode (215) of the electrical source, the pure carbon rod positioned corresponding to the carbon rod and including carbon-12 isotopes; and (c) producing an arc discharge between the carbon rod and the pure carbon rod, wherein the carbon isotope segments of the carbon rod are consumed sequentially to form the isotope-doped carbon nanotubes on a surface of the pure carbon rod. Growth mechanisms of the isotope-doped carbon nanotubes manufactured by this method can be readily studied.

Abstract: A non-thermal plasma assisted combustion fuel injector that uses an inner and outer electrode to create an electric field from a high voltage power supply. A dielectric material is operatively disposed between the two electrodes to prevent arcing and to promote the formation of a non-thermal plasma. A fuel injector, which converts a liquid fuel into a dispersed mist, vapor, or aerosolized fuel, injects into the non-thermal plasma generating energetic electrons and other highly reactive chemical species.

Abstract: The present invention relates to an ablative thermolysis reactor (12) comprising a reaction vessel (20), and inlet (14) into the reaction vessel (20) for receiving feedstock, and an outlet from the reaction vessel (20) for discharging thermolysis product. Within the reaction vessel (20), is provided an ablative surface (20a) defining the periphery of a cylinder, and heating means (22) are arranged to heat the ablative surface (20a) to an elevated temperature. In addition at least one rotatable surface (28) having an axis of rotation coincident with the longitudinal axis of said cylinder. The rotatable surface (28) is provided relative to the ablative surface (20a) such that feedstock is pressed between a part of the rotatable surface (28) and said ablative surface (20a) and moved along the ablative surface (20a) by the rotatable surface (28), whereby to thermolyse said feedstock.

Abstract: A portable, lightweight, easy-to-carry, reusable, durable, and environmentally-friendly assembly for sterilizing contaminated equipment using conditions of a chemical sterilant, heat, and humidity generated in situ without requiring external electricity, fuels, or other exogenous energy sources for operation. The carry assembly includes a plastic carry-case or insulated aluminum pressure vessel having an inner chamber for accepting microbiologically contaminated objects, a vessel disposed in the chamber for serving as a reaction chamber and/or boiler, a chemical combination which upon mixing generates at least minimally sufficient conditions of the sterilant, heat, and humidity to effect sterilization of the objects, and outlet valves mounted on the carry-case for controllably venting pressures above ambient air pressure.

Abstract: An apparatus for deactivating medical instruments and devices comprised of a deactivation chamber movable between a loading position and a deactivation position. A circulation system is provided to circulate a deactivating fluid through the deactivation chamber. The circulation system is connectable to the deactivation chamber when the deactivation chamber is in the deactivation position.

Abstract: A sterilizer, which is not large, but includes a hermetic container capable of defining a sealed space therein without being closed by a locking device from the outside, is disclosed. The sterilizer includes a hermetic container, which defines therein a steam chamber for conducting the heat sterilization of objects. The hermetic container includes a steam supply unit for supplying hot steam to the steam chamber, and an opening/closing unit for closing the steam chamber. The opening/closing unit includes an opening for passing the objects and a door for closing the opening from the inside of the chamber. The door is moved to come into contact with the opening from the inside, and the steam pressure inside the steam chamber is increased by the pressurized steam from the steam supply unit, so that the door can come into close contact with the opening, thus hermetically sealing the steam chamber.

Abstract: This invention relates to a process for beneficiating a titaniferous ore. The process comprises leaching the titaniferous ore with sulfuric acid to form a leached ore, calcining the leached ore in the presence of oxygen to form a calcined ore, and leaching the calcined ore with sulfuric acid, hydrochloric acid, and/or nitric acid to form a beneficiated ore. The leached ore is not reduced prior to or following calcination.

Abstract: A process and system for removing sulfur oxide, other gases, and particulate from a flue gas. The process includes treating flue gas with a slurry formed from water, an alkaline reagent, and the purge stream from a wet scrubber in a spray dryer, thereby producing a dry by-product. The process further includes filtering the flue gas to remove at least a portion of the dry by-product, wet scrubbing the flue gas exiting the filter in a wet scrubber, adding a lime or limestone reagent to the wet scrubber, and producing gypsum. Activated carbon may be injected into the flue gas upstream of the filtering step and particulate may be removed from the flue gas upstream of the spray dryer.

Abstract: The invention provides a process and filter for catalytic purification of exhaust gas from a diesel engine by passing the exhaust gas through a wall flow filter provided with material being catalytic active in the reduction of nitrogen oxides to nitrogen and oxidation of carbonaceous compounds to carbon dioxide and water. The wall flow filter is prepared from silicon carbide and provided with a layer of titanium dioxide on its surface and wherein the catalytic active material comprises oxides of vanadium, tungsten and metallic palladium.

Abstract: A process for producing a purified gas stream from a feed gas stream comprising contaminants, the process comprising the steps of: (a) removing contaminants from the feed gas stream to obtain the purified gas stream and a sour gas stream comprising H2S and RSH; (b) separating the sour gas stream comprising H2S and RSH into a gas stream enriched in H2S and a residual gas stream comprising RSH; (c) converting H2S in the gas stream enriched in H2S to elemental sulphur in a Claus unit, thereby obtaining a first off-gas stream comprising SO2; (d) converting SO2 in the first off-gas stream comprising SO2 to H2S in a Claus off-gas treating reactor to obtain a second off-gas stream comprising H2S; (e) converting RSH from the residual gas stream comprising RSH to H2S in an RSH conversion reactor to obtain a residual gas stream comprising H2S, wherein at least one of the operating conditions of the RSH conversion reactor is different from the corresponding operating condition of the Claus off-gas treating reactor.

Abstract: A method for removing fluorine gas from a selected environment comprises contacting the fluorine gas with water to generate a solution of hydrofluoric acid and contacting the solution of hydrofluoric acid with an ion exchange resin having an active state operative to exchange selected ions therein for fluoride ions in the solution. The apparatus (200) may include a dual resin setup (222, 223) such that one of the ion-exchange resin can be in the service cycle while the other of the ion-exchange resins undergoes the regeneration and rinse/refill cycles.

Abstract: The invention provides a method for purifying silicon which comprises a step of blowing a treating gas generated by reacting carbon with an oxidized gas into a molten silicon, as well as silicon produced by the method. Carbon can be held in a container, the oxidized gas can be passed through the container, and the oxidized gas can contain at least one of water vapor and hydrogen.

Abstract: Methods for the production of monometal carbides are disclosed. A metal source and a carbon source are reacted under conditions suitable to produce a reaction product. The reaction product may comprise fully carburized monometal carbide and excess carbon, or an intermediate product comprising partially carburized monometal carbide in the presence or absence of excess carbon. The carbon content in the reaction product may then be adjusted in a controlled removal or addition process to produce a product the fully carburized monometal carbide having near stoichiometric carbon.

Abstract: Provided is a production process for a carbonized product characterized by comprising the following steps (a) to (b): (a) a step in which metal-made or ceramic-made plural granular matters are charged into a heat treating apparatus which is maintained at a temperature of 400° C. or higher and 700° C. or lower and allowed to move therein and in which a carbonized product precursor is fed into the above apparatus and subjected to heat treatment, whereby the carbonized product is adhered on the surface of the above granular matters and (b) a step in which the carbonized product adhered on the surface of the granular matters is heated at a higher temperature than the heat treating temperature in the step (a) and 900° C. or lower, whereby the carbonized product is separated from the granular matters. The present invention provides a production process for an inexpensive and useful carbonized product by simple apparatus and steps.

Abstract: A method for manufacturing open-ended carbon nanotubes is described. The method includes steps of: providing a substrate having a catalyst layer formed thereon; placing the substrate in a reaction chamber; introducing a carbon source gas containing carbon element into the reaction chamber for growing carbon nanotubes form the catalyst layer; promptly reducing a concentration of the carbon source gas when the growth of carbon nanotubes in process, thereby ceasing the growth of the carbon nanotubes instantly; and separating the carbon nanotubes from the catalyst layer.

Abstract: A process for producing a tape-like material uniformly containing highly pure single-walled or multi-walled carbon nanotubes and a tape-like material produced thereby; a high-performance field emission electrode including the tape-like material; and a process for producing the field emission electrode. The carbon nanotubes are synthesized by arc discharge, wherein an inert gas or inert gas-containing mixed gas is jetted onto a cathode having a carbon material from the inside of a hollow electrode (11) used as an anode, and simultaneously an arc is generated to form a path of arc discharge along a stream of the gas. At the same time, by relative movement of the electrodes, the cathode spot of the arc is moved on the cathode, and the synthesized carbon nanotubes are formed into a tape.

Abstract: The invention relates to alkaline-earth or rare-earth metal aluminate precursor compounds, to their method of preparation and to their use in particular as phosphor precursors. These alkaline-earth or rare-earth metal aluminate precursor compounds are essentially crystallized in the form of a transition alumina and in the form of substantially spherical and chemically homogeneous particles including pores whose mean diameter is of at least 10 nm.

Abstract: A hydrogen storage material. The hydrogen storage material is a combination of LiBH4 with MHx. In one embodiment, x is 0 to 3. In one embodiment, greater than about 50% of M comprises Ti, V, Cr, Sc, Fe, or combinations thereof.

Abstract: Liquid nanoscale particle precursor materials for generating nanoscale particles include at least one high volatility carrier and a second component. A nanoscale particle generating device generates nanoscale particles by passing a liquid nanoscale particle precursor material through a flow passage heated to convert the carrier into a vapor and the second component into nanoscale particles. The nanoscale particles preferably consist essentially of the second component and can consist essentially of dry, solid particles. The particle generator can be incorporated in a hand held inhaler, and can be delivered to a targeted portion of the lung using the inhaler. Composite controlled release particles of micron or nanoscale size can be produced by flowing a solution of medicament, control release agent and carrier liquid through a capillary heater.

Abstract: The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

Abstract: A enhanced method for observing tumor progression, angiogenesis and/or metastasis in animal models in real time is described. The invention employs a skin flap over the area to be observed that can be opened and closed reversibly. The invention also permits simultaneous observation of more than one tumor by use of multiple colors.

Abstract: Two-part dental impression material curable by a metathesis reaction comprising a base paste with first and second resin components each containing at least two cycloolefin groups per molecule curable by a metathesis reaction with a metathesis catalyst. The first resin includes a urethane polyether or polyester carboxylate backbone terminated with the cycloolefin groups and the second resin includes an alkoxy-siloxane polyether or polyester carboxylate backbone terminated with the cycloolefin groups. The metathesis catalyst can be a ruthenium carbene complex catalyst.

Abstract: According to an aspect of the present invention, bioactive polymers are provided which have (a) a hydrophilic bioactive portion and (b) at least one hydrophobic polymer group that is linked to the hydrophilic bioactive portion by a covalent linkage that contains a chain transfer agent residue. According to another aspect of the present invention, medical articles are provided with bioactive surface by coating them with a coating material that contains such bioactive polymers.

Abstract: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.

Abstract: The present invention provides a method for treating cognitive decline in a patient by administering to the patient at least about 100 units per day of ?-interferon.

Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli in various settings.

Abstract: Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor.

Abstract: Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise adminstering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.

Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.

Abstract: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody derivative is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.

Abstract: There is described a method of magnetically manipulating a cell in vivo which comprises the association of a magnetizable particle with a cell. More particularly, there is described a method of magnetically manipulating a cell which comprises the association of a magnetizable particle with a cell characterized in that the method comprises agonizing or antagonizing ion channels within a cell by the association of a magnetizable particle with a cell. There is also described the use of a magnetizable particle in a method of magnetically manipulating a cell in vivo and/or activating ion channels in vivo.

Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

Abstract: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo.

Abstract: This invention relates to the area of immunology and virology, and specifically relates to compositions obtainable from mammalian thymus cells which are useful as diagnostics, vaccines, and therapeutics for human immunodeficiency virus (HIV) infection and related diseases such as acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). The diagnostic, vaccination, and therapeutic methods, and devices, using these compositions are also disclosed.

Abstract: The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.

Abstract: The present invention is directed to a method of enhancing the immune response of a patient relative to the normal immune response, by administering isoaspartyl-modified proteins, peptides, or cells, to a patient. The present invention is also directed to vaccines containing the isoaspartyl-modified proteins, peptides, or cells, as well as antibodies reactive with the isoaspartyl-modified proteins, peptides, or cells.

Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

Abstract: The present invention provides methods of purifying adeno-associated virus (AAV) from compositions comprising AAV and at least a second, non-AAV; and methods for selectively inactivating a non-adeno-associated virus (non-AAV) in a liquid composition comprising AAV and the non-AAV. The methods generally involve subjecting the composition to hydrostatic pressure such that the non-AAV is selectively inactivated.

Abstract: Disclosed herein are antigens that stimulate protective antibodies against enterotoxigenic Escherichia coli. Also disclosed herein are proteins encoded by cssA and cssB genes as well as constructs containing the genes and methods of using thereof.

Abstract: Recombinant Mycobacterium strains with improved vaccinal properties for use as vaccinating agents are provided. The parent strains of the recombinant Mycobacterium strains are selected for their potent immunogenicity. The Mycobacterium strains do not display antibiotic resistance, and do not exhibit horizontal transfer to gram-negative bacteria.